↓ Skip to main content

Dove Medical Press

Article Metrics

Prevention of COPD exacerbation by lysozyme: a double-blind, randomized, placebo-controlled study

Overview of attention for article published in International Journal of Chronic Obstructive Pulmonary Disease, April 2016
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (58th percentile)
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
3 tweeters

Citations

dimensions_citation
5 Dimensions

Readers on

mendeley
9 Mendeley
Title
Prevention of COPD exacerbation by lysozyme: a double-blind, randomized, placebo-controlled study
Published in
International Journal of Chronic Obstructive Pulmonary Disease, April 2016
DOI 10.2147/copd.s103105
Pubmed ID
Authors

Yoshinosuke Fukuchi, Koichiro Tatsumi, Hiromasa Inoue, Yukinori Sakata, Kai Shibata, Hideaki Miyagishi, Yasuhiro Marukawa, Masakazu Ichinose

Abstract

Lysozyme (mucopeptide N-acetyl-muramyl hydrolase) is widely used as a mucolytic and anti-inflammatory agent in Japan. We evaluated the effects of long-term lysozyme administration on COPD exacerbation. In a 1-year, randomized, double-blind, placebo-controlled, parallel trial, patients with moderate-to-severe COPD and one or more episodes of COPD exacerbation in the previous year before enrollment were selected. Lysozyme (270 mg) or placebo was administered orally for 52 weeks as an add-on to the standard therapies such as bronchodilators. COPD exacerbation, pulmonary function, and COPD assessment test scores were analyzed. An exacerbation was defined as worsening of more than one symptom of COPD (cough, sputum volume, purulent sputum, or breathlessness) leading to a change in medication. The primary endpoint was exacerbation rate. A total of 408 patients were randomly assigned to the lysozyme and placebo groups. The baseline characteristics were similar between the two groups. The exacerbation rate was not significantly different between the two groups (1.4 vs 1.2; P=0.292, Poisson regression). However, a subgroup analysis showed that lysozyme might reduce exacerbation rate in patients with airway-dominant phenotype (1.2 vs 1.6). Moreover, the median time to first exacerbation was longer in patients with airway-dominant phenotype in the lysozyme group than that in the placebo group. The levels of improvement in forced expiratory volume in 1 second and COPD assessment test scores were not statistically different between the groups, but were always greater in the lysozyme group than in the placebo group over the 52 weeks of the study. The effects of using lysozyme as an add-on to standard COPD therapy were not significantly different compared with placebo and were insufficient to prevent COPD exacerbation.

Twitter Demographics

The data shown below were collected from the profiles of 3 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 9 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 9 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 4 44%
Researcher 2 22%
Student > Postgraduate 1 11%
Professor 1 11%
Unknown 1 11%
Readers by discipline Count As %
Medicine and Dentistry 6 67%
Nursing and Health Professions 1 11%
Unknown 2 22%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 April 2016.
All research outputs
#3,183,003
of 7,625,034 outputs
Outputs from International Journal of Chronic Obstructive Pulmonary Disease
#398
of 959 outputs
Outputs of similar age
#106,822
of 267,376 outputs
Outputs of similar age from International Journal of Chronic Obstructive Pulmonary Disease
#35
of 65 outputs
Altmetric has tracked 7,625,034 research outputs across all sources so far. This one has received more attention than most of these and is in the 56th percentile.
So far Altmetric has tracked 959 research outputs from this source. They receive a mean Attention Score of 4.2. This one has gotten more attention than average, scoring higher than 55% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 267,376 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 58% of its contemporaries.
We're also able to compare this research output to 65 others from the same source and published within six weeks on either side of this one. This one is in the 43rd percentile – i.e., 43% of its contemporaries scored the same or lower than it.